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the 646 records found, 108 studies met the inclusion criteria (29 cost-effectiveness 
studies (CES) and 81 systematic reviews on effectiveness (SRE)). The majority of 
CES addressed adherence (55%), followed by inappropriate prescribing (31%) and 
prescribing errors (28%). No studies addressed the full medicines pathway. A simi-
lar picture emerged for SRE at 67%, 15 and 11 respectively. Among the 15 types of 
outcomes used in CES, the top three were clinical (31%) measures of adherence 
(21%) and quality-adjusted life years (17%). In SRE, hospitalisations (43%), measures 
of adherence (23%) and mortality (21%) were the most frequent. ConClusions: 
Interventions to improve suboptimal use of medicines tend to be specific to a par-
ticular aspect of the pathway and/or to a particular disease area. Little considera-
tion is made on how to improve medicines use in patients with co-morbidities and 
poly-medication. The medicines pathway is rarely examined holistically but in a 
fragmented manner, making it difficult to draw conclusions on which aspect of 
suboptimal use of medicines should be prioritised for investment.
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THe effecT of Reduced oR Removed coPaymenTs foR PRescRiPTion 
medicines on adHeRence – a sysTemaTic Review
Sinnott S.J., Sinnott C.M., Whelton H.
University College Cork, Cork, Ireland
objeCtives: To examine the effect of removal or reduction in prescription copay-
ments, in the absence of disease management plans, on adherence to prescription 
medications. Methods: Six electronic databases were systematically searched 
for relevant articles, along with hand searches of references in review articles and 
the included studies. Studies were included if they involved an intervention which 
reduced or removed copayments and if the outcome was objectively measured 
adherence. Study designs permitted were randomised controlled trials, time series 
analyses, controlled before/after studies and cohort studies. Studies were excluded 
if the intervention was part of a disease management plan. Study exclusion, data 
extraction and quality appraisal were carried out by two independent reviewers. 
Data were qualitatively synthesised. Results: Nine out of 40 studies were included. 
One study was an RCT; the remainder were all controlled before/after studies. 
There were 144,991 cases and 125,057 controls in this review. The mean age was 
54.39yrs and 55.21yrs for the cases and controls respectively. 44.79% of the cases 
were female, whereas 49.54% of the controls were female. Four studies analysed the 
effect of reduced copayment, 4 studies analysed the effect of a removed copayment 
and 1 study analysed both. Only one study received a strong quality assessment, 
one study was rated as moderate, and the remainder were rated as weak. Seven 
studies showed a significant improvement in adherence. Two studies did not show 
an improvement in adherence. ConClusions: This review concludes that there 
is some evidence of small increases in adherence on the removal or reduction of 
copayments. However, confounders and biases between the included studies were 
variable. Future studies should concentrate on establishing associations between 
reduced cost-sharing and clinical and economic outcomes.
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PRevalence of PHysicians causing PoTenTial dRug inTeRacTions in 
ambulaToRy caRe in swiTzeRland: a RePResenTaTive naTional suRvey
Bucher H.C.
Basel Institute for Clinical Epidemiology & Biostatistics, Basel, Switzerland
objeCtives: No representative data on the quality of drug prescription exist in 
Switzerland. We analysed potential drug interactions (PDI) in primary care based 
on prescription data from 2010 from three large health insurers. Methods: In our 
study population we identified based on the national drug formulary 494 drug-
drug interactions (DDI) classes. Of those, 41 were from drug interaction severity 
classes I (contraindicated) and II (potentially contraindicated) and classified as PDI. 
PDI were calculated for two indicators with different denominators, 1) the total 
number of DDI and 2) the total number of patients potentially exposed to a PDI. 
For each physician we calculated the probability that the number of caused PDI 
was unlikely (p-value between 0.05 and 0.01; ‘problematic prescription behaviour’) 
and very unlikely (p-value < 0.01; ‘likely problematic prescription behaviour’) to be 
explained by chance. Results: Of 3.13 million individuals 1.34% were exposed to 
at least one PDI; figures increased to 3.78% and 4.40% in females and males aged 
≥ 70 years. Of 20,710 physicians 42% caused at least one PDI. With DDI being the 
denominator 6.2% und 3.4% of general practitioners and 0.9% und 0.5% of specialists 
were classified with a ‘problematic’ and ‘likely problematic prescription behaviour’. 
With the patient population being the denominator between 0.96% and 6.22% of 
physicians from all specialty groups had caused a PDI that was classified as ‘likely 
problematic’ (p-value < 0.01). When combining both indicators 457 of 20‘720 physi-
cians (2.2%) had a prescription behaviour causing a PDI that in comparison to peers 
was highly unlikely to be explained by chance (p-value < 0.01). ConClusions: A 
total of 2.2% of physicians in primary care prescribe during one year at least one 
drug combination that is classified as PDI. A linkage to other data sources would 
be needed to further classify PDI that put patients at serious risk for adverse drug 
reactions.
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a sysTemaTic evaluaTion of dRug-dRug inTeRacTions in 
PRescRiPTions; facTs and comPaRisons
Ahmad M., Arshad W., Usman Minhas M.
The Islamia University of Bahawalpur, Bahawalpur, Pakistan
objeCtives: The study focus was to evaluate and compare the prescriptions for 
the encountered potential drug-drug interactions (pDDIs) and their different levels 
on the basis of onset, severity and documentation status, in a tertiary care hos-
pital and community pharmacies in Bahawalpur, Pakistan. Methods: Total 800 
prescriptions, 400 from a tertiary care teaching hospital and 400 from community 
pharmacies, fulfilling inclusion criteria were collected thrice a week during a period 
of three months and were analyzed for potential drug-drug interactions using dug 
digest database, drug interaction checker of www.drugs.com and reference text 
prescribed those drugs from DPC/PDPS data collected between 1st April 2010 and 
31st March 2012 at 1139 of acute care hospitals in Japan. Hospitals were classified 
into five categories (university, private, publi, social insurance group, and others). 
SQL Server 2008 R2 was used for data handling, R for data analysis, and ArcGIS for 
statistical analysis of geography. Results: Generic drugs were least used amongst 
almost all types of drugs in university hospital and social insurance group. For 
prescription of generic drugs, private hospital was the most proactive, followed 
by public hospital. It was revealed, thorough comparison between 20% of medical 
care institutions that are the most proactive towards introduction of generic drugs 
and 20% of the least proactive, that the shifting progress was slower in bigger size 
medical care institutions. ConClusions: This study indicated that for effective 
promotion of generic drugs, it is important to establish plans for changing the policy 
of medical care institutes, which are amongst the bottom 20% of introduction rate, 
where a policy maker does not shift to generic drugs even in the area of expensive 
drugs such as anti anticancer agents and radio contrast agents.
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HealTH TRansfoRmaTion PRogRam imPacT on imPoRT and local 
PHaRmaceuTical consumPTion in TuRkey
Ufuktepe B.1, Kockaya G.2
1Istanbul University, Istanbul, Turkey, 2Health Economics and Policy Association, Ankara, Turkey
objeCtives: Health Transformation Program(HTP) started in year 2003 by MoH of 
Turkey. All health system changed dramatically. It had impact on all health con-
sumptions and expenditures. The aim of this study is to show the impact of HTP 
on the imported pharmaceuticals(IP) and local manufactured pharmaceutical(LMS) 
sales in Turkey. Methods: Pharmaceutical retail sales data in units and 
volume(US$) from year 1998 to 2012 were retrieved from IMS Dataview. Local and 
import consumption trends were reviewed. The data was analyzed with Microsoft 
Excel 2010. Results: Total unit sales were 689M in 1998, 698M in 2002 and 1768 M 
in 2012; after 10 years of HTP. Total sales were 1937M, 2526M and 8000 M USD for 
the same years, respectively. Between 1998 and 2012, CAGR(Cumulative Annual 
Growth Rate) of unit sales was 7%, while the majority of this growth came from 
HTP(9,7% after HTP vs 0,3% before HTP). There was no significant change in unit 
sales between 1998 and 2002; total CAGR was 0,3%. Sales between 1998 and 2012 in 
USD had an average growth rate of 10,7%. Comparing CAGR for before and after HTP; 
LMP was 1,5% before and 7% after while IP showed an inverse ratio with the total 
and LMP values and was 23,5% and 13,1% before and after. In the beginning of the 
15 years period market share for local manufacturing 92,6% in units and 80,8% in 
USD; in 2002 dropped down to 88,8% in units and 65,7% in USD, and finally in 2012 to 
75,2% in units and 49,8% in USD. ConClusions: The percentage of IP both in units 
and volume increased in years. This increase may be caused by different reasons, 
particularly new oncology and biotechnology molecules. It was observed that the 
volume increase in IP or decrease in LMP was limited by the HTP.
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undeRsTanding PaTTeRns of moniToRing of aPPRoPRiaTe PRescRibing 
in euRoPe
Schroeder C.1, Keja J.2, Hughes B.2, Toussi M.3
1IMS Health, Munich, Germany, 2IMS Health, London, UK, 3IMS Health, Paris La Défense, France
objeCtives: To analyse the current requirements and patterns for drug use moni-
toring in Europe and highlight new ways for pharmaceutical companies to meet 
these requirements Methods: We combined three methods of data collection to 
characterise current requirements and patterns for drug use monitoring: 1) review of 
official reports by European agencies; 2) analysis of data elements on the European 
Medicines Agency (EMA) website; and 3) interviews with experts from pharma-
ceutical companies, facing requirements for conducting drug utilisation studies 
(DUS). Results: The recent Good Vigilance Practice (GVP) established a clear regula-
tory framework for drug safety monitoring and calls for the assessment of the effec-
tiveness of risk minimisation measures (RMMs). This should include the evaluation 
of their implementation and outcome. DUS provide simple metrics for monitoring 
of appropriate drug use, and thus the implementation of RMMs. We identified 28 
drugs with DUS in their risk management plan and an additional 23 DUS requested 
by EMA. We observed a top total number of requests for DUS in the fields of contra-
ception (n= 10), infectious diseases (mainly HIV and hepatitis) (n= 8) and diseases 
of the metabolism (mainly diabetes) (n= 6) and less for other therapeutic areas. The 
main reasons for DUS requests were monitoring of off-label use (n= 30) and new 
safety concerns (n= 27). Experts confirmed an increasing demand for DUS. In order 
to optimise the RMMs, repetitive DUS in different points in time are necessary. This 
study analyses DUS’ critical data elements allowing for the automation of such 
measurements. ConClusions: Current and future EMA practice for DUS seems 
to focus on new active substances, particularly in diseases of high public health 
relevance and infectious diseases. To meet this demand, pharmaceutical compa-
nies are required to propose more repetitive measurements of the drug use. This 
study identifies data elements allowing for the automation of such measurements.
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caTcHing THe low-Hanging fRuiT in medicines oPTimisaTion
Faria R., Sculpher M.J.
Centre for Health Economics, York, UK
objeCtives: The medicines bill in high income countries accounts for approxi-
mately 17% of total health care expenditure. However, around $500 million could 
be saved a year worldwide by optimising medicines use. This study aims to scope 
the evidence on the effectiveness and cost-effectiveness of interventions to 
address suboptimal use of medicines and pinpoint the evidence gaps to prioritise 
future research. Methods: Systematic searches (up to February 2013) of the NHS 
Economic Evaluation Database, the Cochrane Database of Systematic Reviews and 
the Database of Abstracts of Reviews of Effects for systematic reviews on effec-
tiveness or cost-effectiveness and for primary research on cost-effectiveness of 
interventions. Studies in English set in any country were included. Results: Of 
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geographical barriers while 63.5% and 58.5 % of them are in front of economic and 
waiting list barriers, respectively. More likely to face economic barriers in access are 
unemployed patients [coef.0.55; 95% CI (0.1, 1)] and patients with low income [-0.2; 
95% CI (-0.26,-0.13)] and lower educational level [-0.04; 95% CI (-0.08, 0)]. Women 
[0.22; 95% CI(0.02,0.42)], low-income patients [-0.13 ; 95% CI(-0.2, -0.06)], and patients 
with lower health status [-0.02 ; 95% CI(-0.02,-0.01)] are more likely to be in front 
of geographical barriers in access. Moreover, all occupational categories examined, 
demonstrate a statistically significant positive relationship with the probability of 
geographical barriers occurrence. In addition, unemployed patients [0.51; 95% CI 
(0.06, 1)], public or private sector employees [0.45; 95% CI (0.09, 0.81)] and low income 
patients [-0.086; 95% CI (-0.15, 0.02)] are more likely to deal with barriers attributed 
to waiting lists. ConClusions: Chronic patients face extensive barriers in access, 
which can mainly be explained by the fall of income, the rise of unemployment 
and the policy of decreasing the supply of certain health services in order to reduce 
health expenditure. If such barriers won’t be minimized inequalities will be enlarged 
and chronic patients’ health status will be worsened which might lead to increased 
future costs and adverse effects on health expenditures.
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QualiTy assuRance of fouRTH HuRdle conceRning To dRugs and 
medical devices
Tesar T.1, Babela R.2
1Union Health Insurance Fund, Bratislava, Slovak Republic, 2St. Elizabeth University of Health and 
Social Sciences, Bratislava, Slovak Republic
objeCtives: From 2011, there are basic thresholds (λ 1= 24 x average monthly sal-
ary € / QALY and λ 2 = 35 x average monthly salary € / QALY) defined directly in the 
Slovak legislation reflecting the benefits displaced elsewhere in the Slovak health 
care system when funds are allocated to new medicines and medical devices. The 
objective of this study was to analyse the quality of submitted economic studies, 
related critical appraisals process and impacts of the new legislation on the access 
to medicines and medical devices. Methods: We created a working group to review 
previously submitted economic evaluations and related critical appraisals in order 
to identify potential technical and methodological problems. The working group 
scrutinized previous submissions and critical appraisals, concerning to chosen ATC 
groups of drugs and groups of medical devices, published between June 2012 and 
June 2013 at the webside of MoH. Results: Pharmacoeconomic evaluations of drugs 
and medical devices within decision making process concerning to reimbursement 
are mandatory but the quality of studies are very often rather poor. The concept “the 
QALY is a tool not a rule” was slightly modified in Slovakia. Our analysis shows that 
implicit thresholds included into the Slovak legislation have influenced decision-
making process concerning to drugs and medical devices. In the defined time period 
4 drugs exceeded the basic thresholds described in the Slovak legislation, however 
108 drugs and medical devices were refused to include into the reimbursement 
list, because of the poor quality of provided pharmacoeconomic studies from the 
side of applicants. ConClusions: The transparent method of HTA can improve 
the consistency of reimbursement decisions making related to drugs and medical 
devices in Slovakia. However significant improvements in the quality of submitted 
pharmacoeconomic dossiers have to be the first step towards the better access to 
drugs and medical devices for the Slovak patients.
PHP55
THe HybRid PuRcHaseR-PRovideR sPliT in england: sHould euRoPe 
follow suiT?
Sewak N.P.S., Devienne E., Karia R.
Double Helix Consulting, London, UK
objeCtives: Developed countries have embraced the purchaser-provider split as 
a mechanism to improve health resource allocation and outcomes. With the emer-
gence of Clinical Commissioning Groups (CCGs) as both buyers and providers of 
health services a hybrid purchaser-provider model is being explored. This research 
explored the opportunities and challenges of this model and analysed the impli-
cations for NHS England and Europe. Methods: Eighty influential regional and 
national payers involved in the NHS England reforms took part in 1-hour tele-depth 
interviews to better understand the changes and uncertainties before the reforms 
were implemented. This research was re-visited three months post implementa-
tion in an advisory board setting to externally validate our findings and identify 
case studies for further analysis. Results: NHS payers stated that they were still 
‘broadly optimistic’ about the re-allocation of purchaser responsibilities to CCGs. 
One case study illustrated that greater clinician involvement provided opportuni-
ties to redesign services like respiratory care and allocate funding more efficiently 
between acute and primary care. Initial success stories include the creation of 
primary care diabetes clinics and Pharma-NHS local partnerships to help reduce 
hospital activity. Within the advisory board, payers voiced concerns with this hybrid 
model. Questions raised from the meeting included: 1) How do we equip GP commis-
sioners with the right skill set to draft and negotiate hospital contracts? 2) How can 
we help GP commissioners and GP providers to help minimise potential conflicts of 
interest? ConClusions: The purchaser-provider model implemented in England 
presents a new way to tackle reduced financial budgets and need to improve health 
outcomes. The results of this research suggest that the purchaser-provider model 
has the potential to make a difference for patient care. A number of challenges 
appear to still be present and it will be important to address these in order for the 
UK and other countries to further explore its benefits.
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cuRRenT sTaTus and evidence of effecTs of e-PRescRibing 
imPlemenTaTion in uniTed kingdom, iTaly, geRmany, denmaRk, Poland 
and uniTed sTaTes
Hermanowski T.R.1, Kowalczyk M.1, Szafraniec-Burylo S.I.2, Krancberg A.N.1, Pashos C.L.3
1Medical University of Warsaw, Warsaw, Poland, 2National Institute of Public Health – National 
Institute of Hygiene, Warsaw, Poland, 3Evidera, Lexington, MA, USA
Drug Interaction Facts. Results: A highly significant difference was observed 
between the prevalence of pDDIs in prescriptions from hospital (45%; 180 out of 
400 prescriptions with at least 1 pDDI) and community pharmacies (29.25%; 117 
out of 400 prescriptions with atleast 1 pDDI). On the whole, out of total 543 pDDIs 
(hospital = 337; community = 206) majority of them were of delayed onset (hospital 
= 50.44%, community = 44.66%), moderate severity (hospital = 57.87%, community 
= 42.72%), suspected type (hospital = 27.6%) and possible documentation (com-
munity = 14.08%). Most of the prescriptions (hospital = 80%; community = 83%) 
contained 2-4 medicines. The interacting combinations such as aspirin-clopidogrel 
omeprazole-clopidogrel and digoxin-furosemide (in hospital); isoniazid-rifampin 
and tramadol-escitalopram were found to be frequently involved in major inter-
actions. The findings showed that cardiovascular drugs were involved in most of 
the rapid pDDIs (in hospital = 32.46%; in community = 33.33%) and respiratory 
system drugs were associated with majority of established documented pDDIs (in 
hospital = 16.67%; in community = 42.86%). ConClusions: Drug-drug interac-
tions in prescription medicines were observed in high percentage both in hospitals 
and community pharmacies. Clinical practices must be standardized as rational 
prescribing practices.
HealTH caRe use & Policy sTudies – equity and access
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unmeT HealTH needs of immigRanTs living in gReece duRing THe 
economic cRisis: THe long-TeRm imPacT foR THe HealTH caRe sysTem
Kaitelidou D.1, Galanis P.1, Zikos D.2, Lemonidou C.1, Chrysopoulou E.1, Bellali T.3, Vafeiadis 
J.4, Siskou O.2, Velonakis E.1
1National and Kapodistrian University of Athens, Athens, Greece, 2Center for Health Services 
Management and Evaluation, National and Kapodistrian University of Athens, Athens, Greece, 
3Alexander Technological Educational Institute of Thessaloniki, Thessaloniki, Greece, 4National 
Organization for the Provision of Health Services (EOPYY), Marousi, Greece
objeCtives: To examine access of migrants in health care services, their unmet 
health needs, and the factors associated with these. Methods: A cross-sectional 
pilot study was conducted from January to May 2013. The study population consisted 
of 231 recent immigrants living in Greece. A questionnaire was developed including 
information about demographics, health status, difficulties in health services access 
etc. Statistical analysis included Pearson’s x2 test, x2test for trend, student’s t-test, 
analysis of variance and Pearson’s correlation coefficient. Results: Almost half of the 
participants (n= 115, 49.7%) used public health services in the last 12 months in Greece. 
Among them, 56.8% (n= 131) used emergency department services. A considerable 
proportion of the participants (n= 144,62.3%), during the last year, needed at least one 
time to use health services but they could not afford it. The most important reasons 
for that were high cost of health care (n= 80, 34.5%) and the long waiting lists (n= 29, 
12.6%). More than half of the participants (n= 122, 52.9%) reported that they had major 
difficulties in accessing health services. Increased family monthly income was associ-
ated with decreased difficulties in access in health services (x2 test for trend= 32.1, 
p< 0.001). The use of preventive services has been limited since more than 60% of 
the women 40+ reported not having conducted a pap test or a mammography, while 
more than 30% of the respondents were not subjected to a blood test or a cholesterol 
examination. ConClusions: Barriers to health services access for migrants may 
lead to decreased use of health services, especially primary, and thus lead to increased 
hospitalizations and higher cost in the longer-run. Formulation of policies to improve 
access and use of health care services are necessary.
PHP52
imPoRTance of subgRouP analyses foR HealTH TecHnology 
assessmenTs
Aggarwal S., Topaloglu H., Kumar S.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: Cost effectiveness analyses play a critical role in determining coverage 
of novel drugs and devices. Increasingly, payers are demanding subgroup analyses 
to determine indications which would be covered by the national health system or 
insurance agency. Methods: To understand and review trends in the use of subgroup 
cost effectiveness analysis, we analyzed NICE HTAs for products approved between 
2011-2012. Manufacturer submissions for CEA were compared to final review and 
decision by HTA agency. Analogs were identified and case studies were developed 
to further understand the use of subgroup analyses and cost effectiveness mod-
els. Results: Decisions made by NICE in 2011-2012 show increasing trends towards 
the use of subgroup analysis for determining indications for coverage by national 
payer bodies. Between 2011-2012, 80% of the assessments included subgroup analy-
ses. Approximately half of them included cost effectiveness analyses for various 
subgroups. Interestingly, the ICER values estimated by NICE for the same subgroups 
showed a large variation (1X-3X fold difference) compared to ICER values estimated 
by manufacturers. Selected case studies highlighted that for several products, NICE is 
recommending treatments only for subgroups whose ICER values are within the cost 
effectiveness threshold. ConClusions: New products need robust broader popula-
tion and subgroup analyses for insurance coverage.
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cHRonic PaTienTs’ access To PHysicians seRvices in Times of economic 
cRisis
Kyriopoulos I.I.1, Skroumpelos A.1, Mylona K.1, Anastasiou L.2, Pavi E.1
1National School of Public Health, Athens, Greece, 2Novartis Hellas, Metamorfosi, Greece
objeCtives: To explore the magnitude of certain access barriers to physician ser-
vices that chronic patients are in front of as well as which patients are more vul-
nerable to such restrictions. Methods: A cross-sectional study was conducted in 
1600 chronic patients suffering from diabetes, hypertension, COPD and Alzheimer. 
Logistic regression analysis was carried out in order to explore the factors related 
to economic and geographical barriers in access, as well as the determinants of 
barriers imposed by waiting lists. Results: A total of 25% of chronic patients face 
